Literature DB >> 1535778

Agonistic and antagonistic effects of antiestrogens in different target organs.

L Kangas1.   

Abstract

Antiestrogens block by definition specifically the actions of estrogens. In the classical uterotropic assay in immature rodents, where estrogens cause fluid retention and cell proliferation, triphenylethylenes have also species-specific estrogen-like (agonistic) effects. 4-hydroxylated triphenylethylenes have in general less estrogenic properties than unhydroxylated ones, and ICI 164,384 has no estrogenic activity in this model. Uterus responds to estrogens by stimulation of cell proliferation. Some other tissues, like breast, liver, and bone respond by regulation of specific protein synthesis. Some of the proteins act as growth factors, and some have unknown functions. The regulation of gene expression is a complex phenomenon: estrogens may turn the responsive gene on or off. Similarly antiestrogens may participate in the gene regulation by mimicking or antagonising estrogen-like actions. This paper summarizes the estrogenic and antiestrogenic effects of classical and new antiestrogens in different tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535778     DOI: 10.3109/02841869209088894

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  6 in total

Review 1.  Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

2.  Toremifene and tamoxifen have similar efficacy in the treatment of patients with breast cancer: a meta-analysis of randomized trials.

Authors:  Qian-Ling Ye; Zhi-Min Zhai
Journal:  Mol Biol Rep       Date:  2014-01-04       Impact factor: 2.316

Review 3.  International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators.

Authors:  Eric R Prossnitz; Jeffrey B Arterburn
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

4.  Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.

Authors:  S Pyrhönen; R Valavaara; H Modig; M Pawlicki; T Pienkowski; S Gundersen; J Bauer; G Westman; S Lundgren; G Blanco; O Mella; I Nilsson; T Hietanen; I Hindy; J Vuorinen; A Hajba
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy.

Authors:  Alka Jindal; Manjit K Mohi; Manjeet Kaur; Balwinder Kaur; Risham Singla; Shaunik Singh
Journal:  J Midlife Health       Date:  2015 Apr-Jun

6.  A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen.

Authors:  Galina Lebedeva; Azusa Yamaguchi; Simon P Langdon; Kenneth Macleod; David J Harrison
Journal:  BMC Syst Biol       Date:  2012-11-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.